United Therapeutics price target raised to $344 from $319 at Ladenburg
The Fly

United Therapeutics price target raised to $344 from $319 at Ladenburg

Ladenburg raised the firm’s price target on United Therapeutics (UTHR) to $344 from $319 and keeps a Buy rating on the shares following the Q3 report. The firm expects the growth of the company’s treprostinil-based products to largely be driven by the growing market potential for Tyvaso. It continues to believe the Tyvaso DPI represents an attractive alternative to the current nebulizer for Tyvaso patients and could be a significant driver for the future expanded uptake of Tyvaso.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App